LRM Aesthetics Introduces Syringe2Syringe Configuration for ariessence pure PDGF+®
New blend-ready configuration streamlines preparation with a pre-configured Syringe2Syringe system
"ariessence pure PDGF+® was developed to provide aesthetic professionals with a scientifically advanced topical formulation designed to complement in-office aesthetic treatments," said Dr.
ariessence pure PDGF+® is a proprietary, pure, potent topical formulation consisting of recombinant, sterile platelet-derived growth factor (PDGF) combined with sterile hyaluronic acid. It is designed to complement professional aesthetic care and can enhance appearance following aesthetic treatments when used following procedures including microneedling, RF microneedling, laser skin resurfacing, and peels.
The new Syringe2Syringe system eliminates the need to draw individual syringes of hyaluronic acid and is designed to deliver precise, consistent quick and easy application with every treatment. The all-in-one treatment system requires no additional components and features a blend-ready design for seamless preparation. Each sterile pack is designed for single-patient use, enabling PDGF+ and hyaluronic acid to be mixed seamlessly while supporting efficient preparation, treatment consistency, and a reduced packaging footprint with 100% recyclable carton components. Each Syringe2Syringe package includes five syringes containing 0.5 ml pure PDGF, five syringes containing 1.5 ml pure HA, and five sterile mixing tips.
"The Syringe2Syringe system makes a meaningful difference in clinical practice because it further streamlines preparation while helping ensure consistency from one treatment to the next," said Dr.
ariessence pure PDGF+® contains only four ingredients: water, sodium acetate, hyaluronic acid, and PDGF (sh-polypeptide-59 dimer). The formulation is manufactured under controlled quality standards and is designed to provide a natural, safe, and consistent topical option for aesthetic providers that is quicker and easier to use than many alternative treatments.
About Lynch Regenerative Medicine, LLC
Lynch Regenerative Medicine, LLC., (www.lynchregen.com) is a commercial stage biotech company advancing regenerative medicine through innovative therapies and aesthetic solutions. Founded by regenerative medicine and PDGF pioneer Dr. Samuel Lynch, the Company develops and commercializes recombinant growth factor products across clearly defined therapeutic indications and cosmetic applications. Its portfolio includes FDA-approved biologics for promoting healing of chronic wounds (Regranex Gel®) and improving periodontal regeneration (GEM 21S®), as well as ariessence pure PDGF+®, a cosmetic product designed to improve the appearance of skin (www.ariessence.com). Through its therapeutics and aesthetics companies, LRM is building a focused regenerative medicine platform grounded in scientific rigor, manufacturing expertise, and a commitment to high-quality biologic innovation. The Company is headquartered in Franklin, Tennessee.
Contact: EvolveMKD, [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/lrm-aesthetics-introduces-syringe2syringe-configuration-for-ariessence-pure-pdgf-302800810.html
SOURCE LRM Aesthetics, Inc
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- The Wealth Company Launches Gift City Fund to Give NRIs a Single, Dollar-Denominated Route into India's Mutual Fund Market
- FRONTERA ANNOUNCES SECOND QUARTER 2026 RESULTS
- SaunaCloud Founder Christopher Kiggins Explains Why Informed Customers Make Better Buyers in New Fast Company Article
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share